Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

CompletadoFase 3ClinicalTrials.gov

ID: NCT04423718Tipo: INTERVENTIONALInicio: 11 de ago de 2020Fin estimado: 7 de ago de 2024

Traducción no disponible, mostrando original

Resumen

In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) in patients suffering from neovascular age-related macular degeneration (nAMD). Neovascular AMD is an eye disease that causes blurred vision or a blind spot due to abnormal blood vessels that leak fluid or blood into the light sensitive lining inside the eye (retina). The fluid buildup causes the central part of the retina (macula) responsible for sharp, straight-ahead vision to swell and thicken (edema), which distorts vision.

Elegibilidad

Edad mínima: 50 YearsSexo: ALL

Criterios de inclusión

Active subfoveal CNV secondary to nAMD, including juxtafoveal lesions that affect the fovea as assessed in the study eye.
Total area of CNV (including both classic and occult components) must comprise greater than 50% of the total lesion area in the study eye.
BCVA ETDRS letter score of 78 to 24 (corresponding to a Snellen equivalent of approximately 20/32 to 20/320) in the study eye.
Decrease in BCVA determined to be primarily the result of nAMD in the study eye.
Presence of IRF and/or SRF affecting the central subfield of the study eye on OCT.
Contraceptive use by men or women should be consistent with local regulations regarding the methods of highly effective contraception for those participating in clinical studies.
At least one BCVA value and one central subfield retinal thickness (CST) value from measurements at one of the following visits: Visit 24 (Week 84), Visit 25 (Week 88) or Visit 26 (Week 92).
Participant is enrolled at a site that participates in the extension period.

Criterios de exclusión

Causes of CNV other than nAMD in the study eye.
Scar, fibrosis, or atrophy involving the central subfield in the study eye.
Presence of retinal pigment epithelial tears or rips involving the central subfield in the study eye.
Uncontrolled glaucoma (defined as IOP \>25 mmHg despite treatment with anti-glaucoma medication) in the study eye.
History of idiopathic or autoimmune uveitis in the study eye.
Myopia of a spherical equivalent of at least 8 diopters in the study eye prior to any refractive or cataract surgery.
History or clinical evidence of diabetic retinopathy, diabetic macular edema, or any retinal vascular disease other than nAMD in either eye.
Evidence of extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in either eye at the time of screening/randomization.
Uncontrolled blood pressure (defined as systolic \>160 mmHg or diastolic \>95 mmHg).
Any prior or concomitant ocular (in the study eye) or systemic treatment (with an investigational or approved, anti-VEGF or other agent) or surgery for nAMD, except dietary supplements or vitamins.

Intervenciones

drug

Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

Solution in Vial, intravitreal (IVT) injection

drug

Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)

Solution in Vial, 2 mg, intravitreal (IVT) injection

Ubicaciones

Organizacion Medica de Investigacion (OMI)

Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

OFTALMOS, Instituto Oftalmologico de Alta Complejidad

Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

Patrocinadores

PrincipalBayer

ColaboradorRegeneron Pharmaceuticals

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

Randomized, Double-Masked, Active-Controlled, Phase 3 Stu... | EligiMed